Janssen licensing agreement for Sepracor's norastemizole readies Hismanal alternative.
JANSSEN READIES HISMANAL REPLACEMENT AS NEW WARNINGS are added to the labeling of the astemizole antihistamine product. Janssen announced Feb. 4 that it is licensing rights to Sepracor's astemizole metabolite norastemizole, giving the company an alternative product that could facilitate the removal of Hismanal from the market.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth